ArticleAnnals of medicine and surgery (2012)2026
Robotic nanoparticle delivery systems for tumor hyperthermia: clinical readiness and challenges.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robotic nanoparticle delivery systems for tumor hyperthermia are redefining precision oncology. By integrating magnetic nanoparticles, robotics, and real-time imaging, these systems enable controlled heating of malignant tissue while sparing adjacent structures. Magnetic nanoparticle hyperthermia employs iron oxide nanoparticles activated by alternating magnetic fields to generate localized heat. Advances in Korea, Germany, and China demonstrate the effectiveness of microrobots and magnetic swarms in enhancing nanoparticle targeting and uniform thermal deposition. Image-guided robotic systems with MRI and ultrasound thermometry further optimize safety and reproducibility. Clinically, Germany's MagForce Nanotherm® device is approved for glioblastoma, with ongoing international trials in prostate and pancreatic cancers. However, consistent dosing, nanoparticle biosafety, and standardized protocols remain pressing challenges. With cross-disciplinary collaboration, robotic hyperthermia could soon become a minimally invasive, targeted option for complex solid tumors. This emerging field underscores the need for ethical transparency and adherence to reporting standards for artificial intelligence in medical technology development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.